• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sotera Health Appoints Karen Flynn to Board of Directors

    11/13/23 7:00:14 AM ET
    $CTLT
    $QTRX
    $SHC
    $WST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $CTLT alert in real time by email

    CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board.

    Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer health products. Prior to this, she held the positions of Chief Commercial Officer and President of Biologics at Catalent. Prior to Catalent, she served as Senior Vice President and Chief Commercial Officer for West Pharmaceutical Services (NYSE:WST), and as President of its Pharmaceutical Packaging Systems business. In addition to her experience leading high-growth businesses, Ms. Flynn brings an extensive background in commercial strategy, strategic planning and innovation and quality management.

    "We are excited to welcome Karen to our Board of Directors," said Michael B. Petras, Jr., Chairman and Chief Executive Officer of Sotera Health. "Karen's extensive commercial expertise in pharmaceutical services will serve as a tremendous asset as we continue to grow. Additionally, her strong Board leadership and governance experience will be valuable as we advance as a public company."

    Ms. Flynn currently serves on the Board of Directors of Quanterix Corporation (NASDAQ:QTRX), where she is a member of the Compensation and Nominating and Governance Committees and on the Board of Directors of Catalent. She has also served on the Board of Recro Pharma, Inc., a specialty pharma and contract development and manufacturing organization, where she was Chair of the Compensation Committee and a member of the Audit Committee.

    Ms. Flynn holds a Master of Science in Engineering from University of Pennsylvania and a Master of Science in Business Administration from Boston University. She completed her Bachelor of Science at the University of Notre Dame.

    About Sotera Health

    Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

    Contacts

    Jason Peterson

    Vice President & Treasurer, Sotera Health

    IR@soterahealth.com

    Kristin Gibbs

    Chief Marketing Officer, Sotera Health

    kgibbs@soterahealth.com

    Source: Sotera Health Company



    Primary Logo

    Get the next $CTLT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CTLT
    $QTRX
    $SHC
    $WST

    CompanyDatePrice TargetRatingAnalyst
    West Pharmaceutical Services Inc.
    $WST
    6/2/2026$375.00Outperform
    Wolfe Research
    Sotera Health Company
    $SHC
    1/9/2026$24.00Neutral → Overweight
    Piper Sandler
    Sotera Health Company
    $SHC
    1/9/2026$24.00Outperform
    RBC Capital Mkts
    Sotera Health Company
    $SHC
    12/18/2025Outperform
    William Blair
    West Pharmaceutical Services Inc.
    $WST
    12/2/2025$285.00Equal-Weight
    Morgan Stanley
    Sotera Health Company
    $SHC
    11/13/2025$19.00Outperform
    BMO Capital Markets
    West Pharmaceutical Services Inc.
    $WST
    9/15/2025$311.00Buy
    Rothschild & Co Redburn
    Quanterix Corporation
    $QTRX
    8/11/2025$5.00Buy → Hold
    Canaccord Genuity
    More analyst ratings

    $CTLT
    $QTRX
    $SHC
    $WST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Sriram Vandana bought $19,878 worth of shares (4,150 units at $4.79), increasing direct ownership by 5% to 87,200 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    9/17/25 10:24:11 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Walt David R bought $984,968 worth of shares (160,000 units at $6.16), increasing direct ownership by 9% to 1,866,933 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    6/13/25 4:39:15 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President & CEO Toloue Masoud bought $248,723 worth of shares (45,900 units at $5.42), increasing direct ownership by 10% to 518,922 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    6/10/25 4:08:44 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTLT
    $QTRX
    $SHC
    $WST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics

    Strategic Leadership Addition Signals Drive to Expand Diagnostics Business Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Geoff Albrecht as Senior Vice President and General Manager of Diagnostics. This strategic hire underscores Quanterix's commitment to transforming its Diagnostics opportunity into a key component of the company's future growth strategy. Starting with Alzheimer's Disease Diagnostics, Albrecht will lead the company's Diagnostics strategy and the development of a comprehensive infrastructure and operational framework necessary to scale Quante

    6/4/26 8:02:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

    Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that senior management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference being held in Miami, FL from June 8-10, 2026. Chief Executive Officer Everett Cunningham will engage in a fireside chat at 1:20 pm ET on Tuesday, June 9, during which he will provide an update on the Company and its strategic priorities. The Company is also scheduling one-on-one investor meetings at the event. Webcast Information The live webcast presentation can be accessed from the Investor Relations section of the company's webs

    6/3/26 8:01:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    West Appoints Michel Lagarde to be President and Chief Executive Officer

    Experienced healthcare and life sciences executive to lead the Company's next phase of growth and innovationEXTON, Pa., June 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that its Board of Directors has appointed Michel Lagarde to be President and Chief Executive Officer (CEO) and a member of the Company's Board of Directors starting August 31, 2026. He succeeds Eric M. Green, who will retire from his roles as President, CEO and Board Chair on that date. The Company also announced as part of the CEO transition that the Board has elected Lead Independent Director Robert F. Frie

    6/1/26 4:30:00 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    $CTLT
    $QTRX
    $SHC
    $WST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Miller Michael Francis converted options into 130 shares and covered exercise/tax liability with 39 shares, increasing direct ownership by 0.27% to 33,795 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    6/1/26 4:06:29 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Klee Ann R. was granted 14,970 shares, increasing direct ownership by 12% to 140,926 units (SEC Form 4)

    4 - Sotera Health Co (0001822479) (Issuer)

    5/27/26 8:27:22 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Chief Executive Officer Shader Alton was granted 579,573 shares (SEC Form 4)

    4 - Sotera Health Co (0001822479) (Issuer)

    5/27/26 5:54:27 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $CTLT
    $QTRX
    $SHC
    $WST
    SEC Filings

    View All

    West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)

    6/1/26 4:32:30 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by Sotera Health Company

    SD - Sotera Health Co (0001822479) (Filer)

    5/29/26 4:05:15 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Quanterix Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Quanterix Corp (0001503274) (Filer)

    5/26/26 5:25:36 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTLT
    $QTRX
    $SHC
    $WST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research resumed coverage on West Pharm with a new price target

    Wolfe Research resumed coverage of West Pharm with a rating of Outperform and set a new price target of $375.00

    6/2/26 8:40:09 AM ET
    $WST
    Medical/Dental Instruments
    Health Care

    Sotera Health upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Sotera Health from Neutral to Overweight and set a new price target of $24.00

    1/9/26 8:33:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    RBC Capital Mkts resumed coverage on Sotera Health with a new price target

    RBC Capital Mkts resumed coverage of Sotera Health with a rating of Outperform and set a new price target of $24.00

    1/9/26 8:12:05 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $CTLT
    $QTRX
    $SHC
    $WST
    Financials

    Live finance-specific insights

    View All

    Quanterix Releases Financial Results for the First Quarter of 2026

    Reports $36.4 million in revenue and approximately $103 million of cash and marketable securities Company prioritizing product roadmap and investing in initiatives to drive commercial effectiveness Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financial results for the first quarter ended March 31, 2026. "We continue to make progress toward achieving cash flow breakeven as we move into a phase of growth now that we have captured the cost synergies from the Akoya acquisition," said Everett Cunningham, President & CEO of Quanterix. "As part of this process, we are focusing our

    5/6/26 4:01:00 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook

    Q1 2026 net revenues increased 10.0%, or 6.5% on a constant currency basis, compared to Q1 2025Q1 2026 net income of $27 million or $0.09 per diluted share, compared to a net loss of $13 million or $0.05 per diluted share in Q1 2025Q1 2026 Adjusted EBITDA(1) increased 10.5%, or 6.9% on a constant currency basisQ1 2026 Adjusted EPS(1) of $0.18, an increase of 29% per diluted shareCompany reaffirms full-year 2026 outlook of 5.0% - 6.5% net revenues growth and 5.5% - 7.0% Adjusted EBITDA growth, both on a constant currency basisCompany announced planned CEO transition in a separate release today CLEVELAND, May 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Compan

    5/5/26 7:03:49 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026

    Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Wednesday, May 6, 2026, at 4:30 p.m. E.T., to discuss its first quarter 2026 financial results. Quanterix will issue a press release regarding its first quarter 2026 financial results prior to the conference call on Wednesday, May 6, 2026, after the market closes. The press release will be posted on the Quanterix website at http://www.quanterix.com/. In conjunction with this announcement, the Company will host a conference call on May 6, 2026, at 4:30 PM ET. The dial-in number for USA & Canada

    4/24/26 8:33:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CTLT
    $QTRX
    $SHC
    $WST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/14/24 4:51:55 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/14/24 4:50:09 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Catalent Inc.

    SC 13G/A - Catalent, Inc. (0001596783) (Subject)

    11/14/24 4:35:03 PM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTLT
    $QTRX
    $SHC
    $WST
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics

    Strategic Leadership Addition Signals Drive to Expand Diagnostics Business Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Geoff Albrecht as Senior Vice President and General Manager of Diagnostics. This strategic hire underscores Quanterix's commitment to transforming its Diagnostics opportunity into a key component of the company's future growth strategy. Starting with Alzheimer's Disease Diagnostics, Albrecht will lead the company's Diagnostics strategy and the development of a comprehensive infrastructure and operational framework necessary to scale Quante

    6/4/26 8:02:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    West Appoints Michel Lagarde to be President and Chief Executive Officer

    Experienced healthcare and life sciences executive to lead the Company's next phase of growth and innovationEXTON, Pa., June 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that its Board of Directors has appointed Michel Lagarde to be President and Chief Executive Officer (CEO) and a member of the Company's Board of Directors starting August 31, 2026. He succeeds Eric M. Green, who will retire from his roles as President, CEO and Board Chair on that date. The Company also announced as part of the CEO transition that the Board has elected Lead Independent Director Robert F. Frie

    6/1/26 4:30:00 PM ET
    $WST
    Medical/Dental Instruments
    Health Care

    Eric M. Green Informs Board of Plans to Retire as President, CEO and Chair of the Board of West Pharmaceutical Services, Inc.

    EXTON, Pa., March 9, 2026  /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) announced today that Eric M. Green has informed the Board of Directors that he plans to retire from his positions as President, Chief Executive Officer and Chair of the Board of the Company once his successor has been hired in order to ensure a smooth transition. The Board is engaging a leading executive recruiting firm to assist with the search for a successor and expects this transition to occur in the second half of 2026. In parallel with today's announcement, the Company is reaffirming the guidance set forth in its February 12, 2026 press release.

    3/9/26 4:30:00 PM ET
    $WST
    Medical/Dental Instruments
    Health Care